DOCSLIB.ORG

Oo-()-No,O Ra50

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oo-()-No,O Ra50 US 2010.0041872A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0041872 A1 DeFrees et al. (43) Pub. Date: Feb. 18, 2010 (54) GLYCEROL LINKED PEGYLATED SUGARS (86) PCT NO.: PCT/US07/80471 AND GLYCOPEPTDES S371 (c)(1), (76) Inventors: Shawn DeFrees, North Wales, PA (2), (4) Date: Jul. 28, 2009 (US); Xiao Zeng, Warrington, PA Related U.S. Application Data (US) (60) Provisional application No. 60/828,208, filed on Oct. Correspondence Address: 4, 2006. LEYDIG VOIT & MAYER, LTD Publication Classification TWO PRUDENTIAL PLAZA, SUITE 4900, 180 (51) Int. C. NORTH STETSONAVENUE C07K I4/745 (2006.01) CHICAGO, IL 60601-6731 (US) (52) U.S. Cl. ........................................................ S30/381 (21) Appl. No.: 12/443,428 (57) ABSTRACT The present invention provides conjugates between peptides (22) PCT Fled: Oct. 4, 2007 and PEG moieties through glycerol linkers. Preparation of CMP-SA-Glycerol-PEG-40kDa Yokn---nor-o 3D. oo-()-No,O rA50 mPEG-40 kDa nitrophenyl carbonate CMP-SA-Glycine 1.2g 30.0 g 1)THF/HO (3:1)rt, 5 days HO OH WP O ONC. 2) NaOH, pH 9.5, 1 hr --norO O O &ay 3) TFF, 1 kDa MWCO O HN CO2 Hó 6 4) Q-sepharose anion exchange Yokn- -1o O N HO *N 3. OH 5) TFF, 1 kDa MWCO O nr-450 CMP-SA-Glycerol-PEG-40 kDa 10.11 g, 36% isolated yield 100% purity by UV Patent Application Publication Feb. 18, 2010 Sheet 1 of 47 US 2010/0041872 A1 FIGURE 1 : eqXOy-?Ed-IoueoÁIÐ-VS-dWOjouo??euedeud Patent Application Publication Feb. 18, 2010 Sheet 2 of 47 US 2010/0041872 A1 FIGURE 2 (6z'))"be'Joucºz }IeSuun?poS (60£)"be'Jou! suoppuoouomoeoseqMOv-03d-IoleoÁIÐ-vs-awo %98p???Á6!L’OLp??glund (aujoÁIÐ-VS-dWo"sauuuyzzAn)Aq?und Patent Application Publication Feb. 18, 2010 Sheet 3 of 47 US 2010/0041872 A1 FIGURE 3 sseoouduo?eo???undeqXOV-9Bd-IoueoÁIÐ-VS-dWO ?eseo(TEHIJ º1, (speeg615) ?sOue?d?S-O Á?deu6O?euol?O Patent Application Publication Feb. 18, 2010 Sheet 4 of 47 US 2010/0041872 A1 FIGURE 4 009 s SQL eQX07-9Bd-IoueOÁIÐ-VS-dWO?ouo?eo??undesoue?des-o '(zuL'OAedKLueelos?euelqeueW eso|n||30p??eJeue6ex;eq>||Oy-l)xz) Patent Application Publication Feb. 18, 2010 Sheets of 47 US 2010/0041872 A1 FIGURE 5 o Tri -1 N T --9. gPage6E E GvR.' r SSP's 938649eA. o of 1 site.BESE-R. S w O s'. wr B7778 E s 999 it (D OSSEF.6'sEaseeviv- N t; (6:1 ? E7WES987 l? s O mism O) -ris a'a () 0. 2. D CD D a a. C el O) ? fl. SS N. e S -1 O w l c Y v O e s s 2 w D N 4. used w s S.O ver ld Patent Application Publication Feb. 18, 2010 Sheet 6 of 47 US 2010/0041872 A1 FIGURE 6A Protein Organism GenBank I GenPept PDB 3D At 1g08280 Arabidopsis thaliana ACO11438 AAF 18241.1 Q84WOO BTOO4583 AAO42829.1 (9SGD2 NC003070|NP 1723.05.1 At1g08660/F22O13.14 n.d. At3.g48820/T21J1890 (X-2,3-sialyltransferase ST3GA-IV N-2,3-sialyltransferase A585768 St3Ga Y-2,6-sialyltransferase AJ620651 CAFO5850.1 Siato (X-2,8-sialyltransferase SIAT8A OC-2,8-Sialyltransferase CAG27883 Siat8D (x-2,8-sialyltransferase ST8Si- (Siat8C CMP X-2,6- sialyltransferase NM 177517|NP 803483.1 ST6Ga fragment -- ST3Ga- (Siat4B --- sialyltransferase BOS taurus n.d. AJ748842 CAG44451.1 ST3Gal-lil (Siates ST3Gal-VI (Siat10 SEVEEEEEEEEStóGalNAc-V Bos taurus n.d. AJ620949 CAF06586.1 Q9BEG4 Branchiostonna n.d. AF391289 AAM18873.1 Q8T771 floridae polysialyltransferase Cercopithecus 24.99.- AF210729 AAF17105.1 Q9TTO9 (PST) (fragment) aethiops ST8Sia IV polysialyltransferase Cercopithecus 2.499.- AF210318 AAF17104.1 Q9TT10 (STX) (fragment) aethiops ST8Sial ST3Gall (Siat4 Ciona Savignyi n.d. Aj626814 CAF25172.1 ST3Gal Siata C-2,8- AAE28634 Q64690 polysialyltransferase CAA86822.1 ST8Sia IV Gal (1,314-GlcNAc C AAP22942.1 2,3-sialyltransferase St3Gal Gall1,314-GlcNAc cy AAP22943.1 2,3-sialyltransferase St3Galil (fragment (X-2,3-sialyltransferase CAHO4017.1 ST3Gal (Siat4 na. Issa. C-2,3-sialyltransferase Danio rerio ST3Galil (Siat5) a first CAHO4018.1 Patent Application Publication Feb. 18, 2010 Sheet 7 of 47 US 2010/0041872 A1 FIGURE 6B Organism EC# GenBank 1 GenPept 3D (X-2,3-sialyltransferase Danio rerio n.d. AJ626821 CAF25,179.1 ST3Gal (Siates C-2,3-sialyltransferase ST3Gal IV (Siat4C cC-2,3-sialyltransferase ST3Gal W-r (Siat5 CC-2,6-sialyltransferase ST6Gal Siat 1 EE-2,6-sialyltransferase A634.459 CAG2.568.0.1 ST6GalNAc Siat/B CC-2,6-sialyltransferase ST6GalNAc V (Siat7E) fragment DC-2,6-sialyltransferase AJ646883 ICAG26712.1 ST6GalNAc VI (Siat7F) fragment X-2,8-sialyltransferase AJ715535 CAG29374.1 ST8Sia I (Siat 8A) (fragment) X-2,8-sialyltransferase AJ715543 CAG2938.2.1 ST8Sia Il (Siat 8C) fragment cC-2,8-sialyltransferase CAG29384.1 ST8Sia IV (Siat 8D) cC-2,8-sialyltransferase AJ715546 CAG29385.1 ST8SiaV (Siat 8E) O-2,8-sialyltransferase AJ715551 CAG29390.1 ST8Sia VI (Siat 8F) fragment galactosamide (X-2,6- sialyltransferase ll ST6Gall N-glycan CX-2,8- n.d. sialyltransferase - ST3Gal-related (siatér) St3Gal-V st6GalNAc-V X-2,6-sialyltransferase Drosophila (CG4871) ST6Gall melanogaster (X-2,3-sialyltransferase ST3Ga-V Gaius gains ind AJ627.204it; CAF25503.1SAE C-2,3-sialyitransferase ST3Gall NM 205217NP 990548.1 (C-2,3-sialyltransferase Gallus gallus 2.4.99.- AFO35250 AAC 14163.1 O73724 ST3Gal IV (fragment (X-2,3-sialytransferase Gallus gallus AJ585761 ICAE51385.2 ST3GAL (X-2,6-sialyltransferase Gallus gallus w CAFO5852.1 Siat/b AJ620653 X-2,6-sialyltransferase Gallus gallus X75558 CAA53235.1 Q92182 ST60sal NM 205241NP 990572.1 co-2,6-sialyltransferase Gallus gallus AAE68028.1 O921.83 Patent Application Publication Feb. 18, 2010 Sheet 8 of 47 US 2010/0041872 A1 FIGURE 6C Protein Organism EC GenBank I GenPept Swiss Prot PDB 3D ST6CalNAc - AAE68029.1 74946 CAA52902. NM 20524ONP 990571.1 C-2,6-sialyltransferase Gallus gallus 2.4.99.- X77775 AAE68030.1 Q921.84 ST6GalNAc NM 205233CAA54813.1 NP 990564.1 C-2,6-sialyltransferase Gallus gallus n.d. AJ634455 CAG2.5677.1 ST6GalNAc III (SIAT7C) fragment (C-2,6-sialyltransferase Gallus gallus AJ646877 ICAG26706.1 ST6GalNAc V (SIAT7E) fragment X-2,8-sialyltransferase Gallus gallus 24.99.- U73176 AAC28888.1 P79783 (GD3 Synthase) ST8Sia X-2,8-sialyltransferase Gallus gallus AJ 6994.19 (CAG27881.1 SAT8B OC-2,8-sialyltransferase Gallus gallus AJ699420 CAG27882.1 SAT8C (X-2,8-sialyltransferase Gallus gallus AJ699424 CAG27886.1 SIAT8F O-2,8-syalyltransferase Gallus gallus AJ704564 CAG28697.1 ST8Six-WSAT8C galactosamide X-2,6- Gallus gallus n.d. A627629 CAF29497.1 sialyltransferase ll ST6Galil Gallus qallus AY515.255 AAS83519.1 polysialyltransferase Gallus gallus ST8Sia IV (X-2,3-sialyltransferase ST3Ga AF059321 L13972 AF155238 AF1861.91 O-2,3-sialyltransferase Q16842 ST3 Ga. OOO654 23768 C-2,3-sialyltransferase BC050380 ST3Galil (SiaT6) AF425851 AF425852 AF425853 AF425854 AAO13862.1 AAO13863.1 AAO13870.1 AAO1387.1.1 Patent Application Publication Feb. 18, 2010 Sheet 10 of 47 US 2010/0041872 A1 FIGURE 6E Protein Organism GenBank I GenPept swapo PDB 3D NM O18414 NP 06.0884.1 F O-2,8- 41680 polysialyltransferase BCO27866 ST8Sia IV BCO53657 AAH53657.1 NM OO5668 NP OO5659.1 X-2,8-sialyltransferase L32867 (GD3 synthase) ST8Sia L43494 BCO46158 AAH46158.1 Q93064 AACR53140.1 AAS75783.1 BAA05391.1 CAA548911 NP 003025.1 (X-2,8-sialyltransferase AAA36613.1 Q92186 ST8Sial B51242.1 Q92470 AAC24458.1 Q92746 BCO69584 AAH69584.1 NM OO6011 NP OO60.02.1 O-2,8-sialyltransferase AFOO4668 AAB87642.1 ST8Sial AFOO3092 AAC 15901.2 NM 015879 NP 056963. cC-2,8-sialyltransferase AAC51727.1 O15466 ENSPOOOOOO20221 (fragment) lactosylceramide X-2,3 24.99.9 AF05026 IAAD 14634.1 Q9UNP4 sialyltransferase AF1194.15 AAF66146.1 O94902 BCO65936 AAH65936.1 (ST3Gal W) AY152815 AAO16866.1 AAP65066 AAP65066.1 AY359105 AAC89463.1 ABO18356 BAA33950.1 CAE893.20.1 N- Homo sapiens BCOO6564 BCOO7802 acetylgalactosaminide BCO 16299 C-2,6-sialyltransferase AY358.672 (ST6GalNAc VI) ABO35173 AKO23900 AU507293 AX880950 N- Homo sapiens AF127142 AAFOO102.1 acetylgalactosaminide BCO36705 AAH36705.1 C-2,6-sialyltransferase AAP63349. IV (ST6GalNAc IV) AB035172 BAA87034.1 BAA91281.1 CAB44354.1 CACO7404.1 CAC24981.1 CAC27250.1 CAF 14360.1 NM_014403 NP 055218.3 NM 175039 NP 7782O4.1 ST8SIA-V1 (fragment) Aj621.583 CAF21722.1 homosen a M 291725 XP 291725.2 unnamed protein Homo sapiens AKO21929 BAB13940.1 Q9HAA9 Oroduct AX881696 CAE91353.1 Gali-1,314-GlcNAc C Mesocricetus 2.499.6 A.J245699 CAB53394.1 O90XF6 Patent Application Publication Feb. 18, 2010 Sheet 11 of 47 US 2010/0041872 A1 FIGURE 6F 1 3D auratus MeSOCricetus auratus pope CAB53395.1 Q9QXF5 MeSOCricetus a Fiates AAD33879.1 Ch9WUL1 auratuS MeSOCricetus 24.99.- AJ2457.01 CAB53396.1 Q90XF4 auratus X-2,3-Sialyltransferase Mus musculus 24.994 AF214028 AAF60973.1 P54751 ST3Gal BAC27356.1 Q11202 AKO78469 BAC37.290.1 73523 CAA51919.1 NM OO9177NP 033203.1 cC-2,3-sialyltransferase St3gal2 MuS nuSCulus AAH15264.1 Q11204 ST3Gal AAH66064.1 BAC28752.1 BAC28859.1 C-2,3-sialyltransferase St3gal3 MuS musculus ST3Gail s 3-Sialyltransferase ST3Gal V (X-2,3-sialyltransferase MuS musculus ST3Gal VI ABO63326 BAB79494.1 AKO33562 BAC2836O1 X-2,6-sialyltransferase Stögalnac2 Mus musculus - P70277 ST6GalNAc BCO10208 AAH102081 Q9DC24 AB027198 BABOO637.1 Q9JJM5 AKOO4613 BAB23410.1 X93999 CAA63821.1 X94000 CAA63822.1 NM OO918ONP 033206.2 or-2,6-sialyltransferase Stögal1 MuS musculus 2.499.1 AAE680311 Q64685 ST6Gall BCO27833 AAH27833.1 Q8BM62 D16106 BAA03680.1 O8K1 L1 AKO34768 BAC288281 AKO84124 BAC39120.1 NM 145933NP 666045.1 CE-2,6-sialyltransferase Stögal2 MuS musculus AKO82566 BAC38534.1 O8BUU4 ST6Gal ABO95093 BAC87752.1 AK1294-62 BAC9827.2.1 NM 172829NP 766417.1 ox-2,6-sialyltransferase Stögalnac1 Mus musculus 24.99.3 Y11274 CAA72137.1 Q9QZ39 NMO 11371 INP 0355011 Q9JJP5 ST6GalNAc (X-2,6-sialyltransferase Stögalnac3 Mus musculus ST6GalNAc Patent Application Publication Feb.
Load more

Recommended publications
  • The Use of Biologic Agents in the Treatment of Oral Lesions Due to Pemphigus and Behçet's Disease: a Systematic Review
    Davis GE, Sarandev G, Vaughan AT, Al-Eryani K, Enciso R. The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review. J Anesthesiol & Pain Therapy. 2020;1(1):14-23 Systematic Review Open Access The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review Gerald E. Davis II1,2, George Sarandev1, Alexander T. Vaughan1, Kamal Al-Eryani3, Reyes Enciso4* 1Advanced graduate, Master of Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 2Assistant Dean of Academic Affairs, Assistant Professor, Restorative Dentistry, Meharry Medical College, School of Dentistry, Nashville, Tennessee, USA 3Assistant Professor of Clinical Dentistry, Division of Periodontology, Dental Hygiene & Diagnostic Sciences, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 4Associate Professor (Instructional), Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA Article Info Abstract Article Notes Background: Current treatments for pemphigus and Behçet’s disease, such Received: : March 11, 2019 as corticosteroids, have long-term serious adverse effects. Accepted: : April 29, 2020 Objective: The objective of this systematic review was to evaluate the *Correspondence: efficacy of biologic agents (biopharmaceuticals manufactured via a biological *Dr. Reyes Enciso, Associate Professor (Instructional), Division source) on the treatment of intraoral lesions associated with pemphigus and of Dental Public Health and Pediatric Dentistry, Herman Ostrow Behçet’s disease compared to glucocorticoids or placebo. School of Dentistry of USC, Los Angeles, California, USA; Email: [email protected].
    [Show full text]
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.468,689 B2 Zeng Et Al
    USOO9468689B2 (12) United States Patent (10) Patent No.: US 9.468,689 B2 Zeng et al. (45) Date of Patent: *Oct. 18, 2016 (54) ULTRAFILTRATION CONCENTRATION OF (56) References Cited ALLOTYPE SELECTED ANTIBODES FOR SMALL-VOLUME ADMINISTRATION U.S. PATENT DOCUMENTS 5,429,746 A 7/1995 Shadle et al. (71) Applicant: Immunomedics, Inc., Morris Plains, NJ 5,789,554 A 8/1998 Leung et al. (US) 6,171,586 B1 1/2001 Lam et al. 6,187,287 B1 2/2001 Leung et al. (72) Inventors: Li Zeng, Edison, NJ (US); Rohini 6,252,055 B1 6/2001 Relton Mitra, Brigdewater, NJ (US); Edmund 6,676,924 B2 1/2004 Hansen et al. 6,870,034 B2 3/2005 Breece et al. A. Rossi, Woodland Park, NJ (US); 6,893,639 B2 5/2005 Levy et al. Hans J. Hansen, Picayune, MS (US); 6,991,790 B1 1/2006 Lam et al. David M. Goldenberg, Mendham, NJ 7,038,017 B2 5, 2006 Rinderknecht et al. (US) 7,074,403 B1 7/2006 Goldenberg et al. 7,109,304 B2 9, 2006 Hansen et al. 7,138,496 B2 11/2006 Hua et al. (73) Assignee: Immunomedics, Inc., Morris Plains, NJ 7,151,164 B2 * 12/2006 Hansen et al. ............. 530,387.3 (US) 7,238,785 B2 7/2007 Govindan et al. 7,251,164 B2 7/2007 Okhonin et al. (*) Notice: Subject to any disclaimer, the term of this 7.282,567 B2 10/2007 Goldenberg et al. patent is extended or adjusted under 35 7,300,655 B2 11/2007 Hansen et al.
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • Presenters: Philip R
    UC Davis Dermatology Online Journal Title Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma Permalink https://escholarship.org/uc/item/8109j4cw Journal Dermatology Online Journal, 20(1) Authors Cohen, Philip R Kurzrock, Razelle Publication Date 2014 DOI 10.5070/D3201021241 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 20 Number 1 January 2014 Case Report Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma Philip R. Cohen, MD1 and Razelle Kurzrock, MD2 Dermatology Online Journal 20 (1): 1 1Division of Dermatology, University of California San Diego, San Diego, California; 2Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California San Diego—Moores Cancer Center, La Jolla, California. Correspondence: Philip R. Cohen, MD 10991 Twinleaf Court San Diego, CA 92131-3643 [email protected] Abstract Background: Anakinra is a recombinant form of interleukin-1 receptor antagonist. It is the drug of choice for Schnitzler syndrome and cryopyrin-associated periodic syndromes. It has also recently been demonstrated to have activity in the treatment of the non-Langerhans cell histiocytosis known as Erdheim-Chester disease. Purpose: To describe the activity of anakinra in a patient with co-existing lichen planus and Erdheim-Chester disease. Methods: A 43-year-old woman with progressive Erdheim-Chester disease presented for management of her night sweats and chills, systemic skeletal bone pain, and neurologic (diabetes insipidus) manifestations. She also had widespread cutaneous lichen planus.
    [Show full text]
  • WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07D 519/00 (2006.01) A61P 39/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 487/04 (2006.01) A61P 35/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/5517 (2006.01) A61P 37/00 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, A61K 47/48 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/IB2013/058229 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2 September 2013 (02.09.2013) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: HANGZHOU DAC BIOTECH CO., LTD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [US/CN]; Room B2001-B2019, Building 2, No 452 Sixth TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Street, Hangzhou Economy Development Area, Hangzhou EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, City, Zhejiang 310018 (CN).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al
    US009 161992B2 (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies et al. (45) Date of Patent: Oct. 20, 2015 (54) P97 FRAGMENTS WITH TRANSFER 4,683.202 A 7, 1987 Mullis ACTIVITY 4,704,362 A 11/1987 Itakura et al. 4,766,075 A 8, 1988 Goeddeletal. (71) Applicant: biosis Technologies, Inc., Richmond 4,800,1594,784.950 A 11/19881/1989 MullisHagen et al. (CA) 4,801,542 A 1/1989 Murray et al. 4.866,042 A 9, 1989 Neuwelt (72) Inventors: Wilfred Jefferies, South Surrey (CA); 4,935,349 A 6/1990 McKnight et al. Mei Mei Tian, Coquitlam (CA): 4.946,778 A 8, 1990 Ladner et al. Timothy Vitalis, Vancouver (CA) 5,091,513 A 2f1992 Huston et al. 5,132,405 A 7, 1992 Huston et al. (73) Assignee: biOasis Technologies, Inc., British 5, 186,941 A 2f1993 Callahan et al. Columbia (CA) 5,672,683 A 9, 1997 Friden et al. 5,677,171 A 10, 1997 Hudziak et al. c - r 5,720,937 A 2f1998 Hudziak et al. (*) Notice: Subject to any disclaimer, the term of this 5,720,954. A 2f1998 Hudziak et al. patent is extended or adjusted under 35 5,725,856 A 3, 1998 Hudziak et al. U.S.C. 154(b) by 0 days. 5,770,195 A 6/1998 Hudziak et al. 5,772,997 A 6/1998 Hudziak et al. (21) Appl. No.: 14/226,506 5,844,093 A 12/1998 Kettleborough et al. 5,962,012 A 10, 1999 Lin et al.
    [Show full text]
  • Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens
    Int. J. Mol. Sci. 2012, 13, 8273-8292; doi:10.3390/ijms13078273 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Phage Display-based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed against Human Pathogens Nicola Clementi *,†, Nicasio Mancini †, Laura Solforosi, Matteo Castelli, Massimo Clementi and Roberto Burioni Microbiology and Virology Unit, “Vita-Salute” San Raffaele University, Milan 20132, Italy; E-Mails: [email protected] (N.M.); [email protected] (L.S.); [email protected] (M.C.); [email protected] (M.C.); [email protected] (R.B.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-2-2643-5082; Fax: +39-2-2643-4288. Received: 16 March 2012; in revised form: 25 June 2012 / Accepted: 27 June 2012 / Published: 4 July 2012 Abstract: In the last two decades, several phage display-selected monoclonal antibodies (mAbs) have been described in the literature and a few of them have managed to reach the clinics. Among these, the anti-respiratory syncytial virus (RSV) Palivizumab, a phage-display optimized mAb, is the only marketed mAb directed against microbial pathogens. Palivizumab is a clear example of the importance of choosing the most appropriate strategy when selecting or optimizing an anti-infectious mAb. From this perspective, the extreme versatility of phage-display technology makes it a useful tool when setting up different strategies for the selection of mAbs directed against human pathogens, especially when their possible clinical use is considered.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Asthma Agents
    APPROVED PA Criteria Initial Approval Date: July 10, 2019 Revised Date: January 20, 2021 CRITERIA FOR PRIOR AUTHORIZATION Asthma Agents BILLING CODE TYPE For drug coverage and provider type information, see the KMAP Reference Codes webpage. MANUAL GUIDELINES Prior authorization will be required for all current and future dose forms available. All medication-specific criteria, including drug-specific indication, age, and dose for each agent is defined in Table 1 below. Benralizumab (Fasenra®) Dupilumab (Dupixent®) Mepolizumab (Nucala®) Omalizumab (Xolair®) Reslizumab (Cinqair®) GENERAL CRITERIA FOR INITIAL PRIOR AUTHORIZATION: (must meet all of the following) • Must be approved for the indication, age, and not exceed dosing limits listed in Table 1. • Must be prescribed by or in consultation with a pulmonologist, allergist, or immunologist.1,2 • For all agents listed, the preferred PDL drug, which treats the PA indication, is required unless the patient meets the non-preferred PDL PA criteria. • Must have experienced ≥ 2 exacerbations within the last 12 months despite meeting all of the following (exacerbation is defined as requiring the use of oral/systemic corticosteroids, urgent care/hospital admission, or intubation: o Patient adherence to two long-term controller medications, including a high-dose inhaled corticosteroid 1,2 (ICS) and a long-acting beta2-agonist (LABA) listed in Table 2. ▪ Combination ICS/LABA and ICS/LABA/LAMA products meet the requirement of two controller medications. o Patient must have had an adequate trial (at least 90 consecutive days) of a leukotriene modifier or a long-acting muscarinic antagonist (LAMA) as a third long-term controller medication listed in Table 2.
    [Show full text]
  • Cimzia (Certolizumab Pegol) AHM
    Cimzia (Certolizumab Pegol) AHM Clinical Indications • Cimzia (Certolizumab Pegol) is considered medically necessary for adult members 18 years of age or older with moderately-to-severely active disease when ALL of the following conditions are met o Moderately-to-severely active Crohn's disease as manifested by 1 or more of the following . Diarrhea . Abdominal pain . Bleeding . Weight loss . Perianal disease . Internal fistulae . Intestinal obstruction . Megacolon . Extra-intestinal manifestations: arthritis or spondylitis o Crohn's disease has remained active despite treatment with 1 or more of the following . Corticosteroids . 6-mercaptopurine/azathioprine • Certollizumab pegol (see note) is considered medically necessary for persons with active psoriatic arthritis who meet criteria in Psoriasis and Psoriatic Arthritis: Biological Therapies. • Cimzia, (Certolizumab Pegol), alone or in combination with methotrexate (MTX), is considered medically necessary for the treatment of adult members 18 years of age or older with moderately-to-severely active rheumatoid arthritis (RA). • Cimzia (Certolizumab pegol is considered medically necessary for reducing signs and symptoms of members with active ankylosing spondylitis who have an inadequate response to 2 or more NSAIDs. • Cimzia (Certolizumab Pegol) is considered investigational for all other indications (e.g.,ocular inflammation/uveitis; not an all-inclusive list) because its effectiveness for indications other than the ones listed above has not been established. Notes • There are several brands of targeted immune modulators on the market. There is a lack of reliable evidence that any one brand of targeted immune modulator is superior to other brands for medically necessary indications. Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), Simponi Aria (golimumab intravneous), and Stelara (ustekinumab) brands of targeted immune modulators ("least cost brands of targeted immune modulators") are less costly to the plan.
    [Show full text]